Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials

Over the last two decades, several epi‐drugs, immune checkpoint inhibitors (ICIs) and adoptive cell therapies have received clinical approval for use in certain types of cancer. However, monotherapy with epi‐drugs or ICIs has shown limited efficacy in most cancer patients. Epigenetic agents have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yang, Li, Ping, Liu, Yang, Xin, Dijia, Lei, Wen, Liang, Aibin, Han, Weidong, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198339/
https://www.ncbi.nlm.nih.gov/pubmed/35642676
http://dx.doi.org/10.1002/cac2.12313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198339/
https://www.ncbi.nlm.nih.gov/pubmed/35642676
http://dx.doi.org/10.1002/cac2.12313

Ejemplares similares